Separate names with a comma.
Current Research, Regulatory, and Policy Considerations Regarding Psychedelics as Medicine (Substance Abuse and Mental Health Services...
States Should Start Planning Now For FDA Approval Of Psychedelics, Federal Report Says...
VA’s Only Drug for Treatment-Resistant Depression Requires Up to 50 Visits a Year...
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift...
ASU-led project to examine psychedelic therapy for mental health...
The White House’s MAHA Gatekeeper - https://www.theatlantic.com/politics/2026/07/heidi-overton-maha-rfk/688038/?utm_source=apple_news Almost...
Why pharmaceutical companies are interested in psychedelics...
Radial Now Supports the Country's Largest Brain Medicine Clinical Network, Expanding Access to Breakthrough Treatments...
DFTX Public Comments on the Request for Information: Training and Care Delivery Models for Safe Administration of Potential FDA-Approved...
VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans...
Newsweek - VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans...
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more [MEDIA]
Definium reports positive results for anxiety treatment https://pharmatimes.com/news/definium-reports-positive-results-for-anxiety-treatment/
$DFTX Targets JonesTrading — $90 Bank of America — $75 Baird — $75 Piper Sandler — $75 Wells Fargo — $72 H.C. Wainwright — $70 Oppenheimer —...
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential...
LSD-based tablet shows promise in new anxiety trial https://www.ktvu.com/video/fmc-mi4k2oneua0ojpzc
